Magnesium Treating Subarachnoid Hemorrhage Vasospasm

• Status: Not yet recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized clinical trial investigating magnesium sulphate ability to reduce risk of cerebral vasospasm after acute subarachnoid hemorrhage hence improving outcome particularly in haptoglobin 2-2 patients who are highly susceptible for severe complications after subarachnoid hemorrhage.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt
• Collaborators: Ain Shams University, Faculty of medicine, Egypt; Health Insurance Organization, Egypt
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Patients of both genders

• age over 18 years old

• diagnosis of acute aSAH (≤ 48 hours) confirmed with angiographic evidence of cerebral aneurysm and CT brain on admission.

Exclusion Criteria:

• subarachnoid hemorrhage due to non-aneurysmal causes

• cerebral stroke of any type during past month

• decompensated heart failure, renal failure or hepatic failure

• difficult bilateral transtemporal transcranial Doppler (TCD) insonation of intracranial arteries due to thick temporal bone of the skull.